Medigus Ltd.

4.95-0.0500-1.00%Vol 8.72K1Y Perf -69.70%
Feb 3rd, 2023 15:55 DELAYED
BID4.92 ASK5.09
Open4.95 Previous Close5.00
Pre-Market- After-Market4.91
 - -  -0.04 -0.81%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.22
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★★     67.47
Price Range Ratio 52W %
3.35 
Earnings Rating
Market Cap8.11M 
Earnings Date
-
Alpha-0.01 Standard Deviation0.33
Beta2.12 

Today's Price Range

4.925.19

52W Range

4.4519.50

5 Year PE Ratio Range

-1.60-0.8000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-1.64%
1 Month
0.20%
3 Months
-19.51%
6 Months
-46.76%
1 Year
-69.70%
3 Years
-80.92%
5 Years
-75.74%
10 Years
-

TickerPriceChg.Chg.%
MDGS4.95-0.0500-1.00
AAPL154.503.68002.44
GOOG105.22-3.5800-3.29
MSFT258.35-6.2550-2.36
XOM111.920.77000.69
WFC47.580.35000.74
JNJ164.61-0.9300-0.56
FB196.640.99000.51
GE81.96-1.9800-2.36
JPM141.092.15001.55
 
ProfitabilityValueIndustryS&P 500US Markets
24.30
-47.90
-43.90
-2 596.40
-13.58
RevenueValueIndustryS&P 500US Markets
35.81M
21.85
-
-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2022 FY-6.450.00-
12/2023 FY-4.800.00-
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume8.72K
Shares Outstanding1.64K
Shares Float491.83M
Trades Count98
Dollar Volume43.56K
Avg. Volume30.31K
Avg. Weekly Volume24.28K
Avg. Monthly Volume15.24K
Avg. Quarterly Volume51.42K

Medigus Ltd. (NASDAQ: MDGS) stock closed at 4.95 per share at the end of the most recent trading day (a -1% change compared to the prior day closing price) with a volume of 8.72K shares and market capitalization of 8.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 26 people. Medigus Ltd. CEO is Liron Carmel.

The one-year performance of Medigus Ltd. stock is -69.7%, while year-to-date (YTD) performance is 6%. MDGS stock has a five-year performance of -75.74%. Its 52-week range is between 4.445 and 19.5, which gives MDGS stock a 52-week price range ratio of 3.35%

Medigus Ltd. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.19, a price-to-sale (PS) ratio of 0.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -8.74%, a ROC of -11.73% and a ROE of -14.50%. The company’s profit margin is -13.58%, its EBITDA margin is -43.90%, and its revenue ttm is $35.81 Million , which makes it $21.85 revenue per share.

Of the last four earnings reports from Medigus Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Medigus Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Medigus Ltd. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Medigus Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Medigus Ltd. has a dividend yield of 15.59% with a dividend per share of $0.80 and a payout ratio of -%.

Medigus Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.78, ATR14 : 0.36, CCI20 : 59.27, Chaikin Money Flow : -0.13, MACD : -0.06, Money Flow Index : 44.45, ROC : -0.20, RSI : 46.50, STOCH (14,3) : 56.20, STOCH RSI : 0.67, UO : 43.26, Williams %R : -43.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Medigus Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Medigus Ltd.

Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.

CEO: Liron Carmel

Telephone: +972 733704691

Address: 3 HaNechoshet Street, Tel Aviv 6971068, , IL

Number of employees: 26

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

67%33%

Bearish Bullish

51%49%


News

Stocktwits